Timeline update on GABA/Diamyd® and Remygen® clinical trials

Preliminary findings and study details of the GABA/Diamyd® trial conducted in the US will be presented by Professor Kenneth McCormick, Principal Investigator and Sponsor, on September 17, 2019 at the Annual Meeting of the European Association for the Study of Diabetes (EASD), in Barcelona, Spain. Final results, including immunological findings and subgroup analyses, are expected later this year and in early 2020.  The dose-escalation part of ReGenerate-1, evaluating the safety, pharmacokinetic properties and short-term metabolic effect of Remygen® is expected to be finalized this autumn.